Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
acknowledged the resubmission of a New Drug Application (NDA) for
ezetimibe and atorvastatin tablets, an investigational combination
medicine. The updated NDA was deemed complete for review after Merck
submitted additional data in response to the FDA’s Complete Response
Letter issued last year.
Language:
English
Contact HTML:
MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Source Type: news
More News: Atorvastatin Calcium | Food and Drug Administration (FDA) | Lipitor | Merck | New Drug Applications | Pharmaceuticals | Statin Therapy | Vytorin | Zetia | Zivast